Bayesian models to estimate causal effects of biological treatments
on time-to-event endpoints in clinical trials with principal strata
defined by the occurrence of antidrug antibodies.
Bornkamp, B., Rufibach, K., Lin, J., Liu, Y., Mehrotra, D. V.,
Roychoudhury, S., Schmidli, H., Shentu, Y., and Wolbers, M. (2021),
“
Principal stratum strategy: Potential role in drug
development,”
Pharm Stat, 20, 737–751.
https://doi.org/10.1002/pst.2104.
Frangakis, C. E., and Rubin, D. B. (2002), “
Principal stratification in causal inference,”
Biometrics, 58, 21–29.
https://doi.org/10.1111/j.0006-341x.2002.00021.x.
Imbens, G. W., and Rubin, D. B. (1997), “Bayesian Inference for Causal
Effects in Randomized Experiments with Noncompliance,”
Ann
Stat, 25, 305–327.
https://doi.org/10.1214/aos/1034276631.
International Council for Harmonisation (ICH) (2020), “ICH E9 (R1)
addendum on estimands and sensitivity analysis in clinical trials to the
guideline on statistical principles for clinical trials.”
https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf.
Lipkovich, I., Ratitch, B., Qu, Y., Zhang, X., Shan, M., and
Mallinckrodt, C. (2022), “Using principal stratification in analysis of
clinical trials,”
Stat Med, 41, 3837–387.
https://doi.org/10.1002/sim.9439.